Trial Profile
Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Postpartum haemorrhage
- Focus Therapeutic Use
- 23 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 27 Sep 2016 New trial record